|
2021-07-20 |
2021-07-19 |
S
Sale
|
Muzikant Adam
Chief Business Officer
Officer
|
1,870
-1.8%
6.45
USD 12,062
|
1,870
-1.8%
|
6.45
|
USD 12,062
|
|
|
2021-05-12 |
2021-05-10 |
S
Sale
|
Arkowitz David
Chief Financial Officer
Officer
|
2,229
-1.0%
7.23
USD 16,116
|
2,229
-1.0%
|
7.23
|
USD 16,116
|
|
|
2021-03-16 |
2021-03-15 |
S
Sale
|
Layman Melissa
Chief Commercial Officer
Officer
|
4,520
-4.2%
11.80
USD 53,336
|
4,520
-4.2%
|
11.80
|
USD 53,336
|
|
|
2021-01-29 |
2021-01-28 |
S
Sale
|
Layman Melissa
Chief Commercial Officer
Officer
|
2,624
-2.9%
12.55
USD 32,931
|
2,624
-2.9%
|
12.55
|
USD 32,931
|
|
|
2021-01-07 |
2021-01-05 |
PS
Planned sale
|
KELLEY SCOTT
Chief Medical Officer
Officer
|
6,829
-5.7%
11.13
USD 76,007
|
6,829
-5.7%
|
11.13
|
USD 76,007
|
|
|
2021-01-07 |
2021-01-05 |
PS
Planned sale
|
Wentworth Kerry
Chief Regulatory Officer
Officer
|
6,829
-5.7%
11.13
USD 76,007
|
6,829
-5.7%
|
11.13
|
USD 76,007
|
|
|
2021-01-07 |
2021-01-05 |
S
Sale
|
Arkowitz David
Chief Financial Officer
Officer
|
6,073
-3.9%
11.13
USD 67,592
|
6,073
-3.9%
|
11.13
|
USD 67,592
|
|
|
2021-01-07 |
2021-01-05 |
S
Sale
|
Muzikant Adam
Chief Business Officer
Officer
|
4,005
-5.2%
11.13
USD 44,576
|
4,005
-5.2%
|
11.13
|
USD 44,576
|
|
|
2021-01-07 |
2021-01-05 |
S
Sale
|
Levine Mark S.
General Counsel
Officer
|
6,829
-6.0%
11.13
USD 76,007
|
6,829
-6.0%
|
11.13
|
USD 76,007
|
|
|
2021-01-07 |
2021-01-05 |
S
Sale
|
Willwerth Christina
Chief Strategy Officer
Officer
|
6,602
-5.4%
11.13
USD 73,480
|
6,602
-5.4%
|
11.13
|
USD 73,480
|
|
|
2020-05-27 |
2020-05-26 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
10,256
+3.0%
9.75
USD 99,996
|
10,256
+3.0%
|
9.75
|
USD 99,996
|
|
|
2020-05-27 |
2020-05-26 |
B
Purchase
|
Stejbach Mark
Non-Executive Director
|
2,051
+inf%
9.75
USD 19,997
|
2,051
+inf%
|
9.75
|
USD 19,997
|
|
|
2020-05-11 |
2020-05-07 |
PS
Planned sale
|
Arkowitz David
Chief Financial Officer
Officer
|
2,413
-2.0%
10.88
USD 26,253
|
2,413
-2.0%
|
10.88
|
USD 26,253
|
|
|
2020-01-07 |
2020-01-03 |
S
Sale
|
KELLEY SCOTT
Chief Medical Officer
|
3,724
0.00
USD 0
|
3,724
|
0.00
|
USD 0
|
|
|
2020-01-07 |
2020-01-03 |
PS
Planned sale
|
Levine Mark S.
General Counsel
|
3,724
0.00
USD 0
|
3,724
|
0.00
|
USD 0
|
|
|
2020-01-07 |
2020-01-03 |
S
Sale
|
Arkowitz David
Chief Financial Officer
|
3,095
0.00
USD 0
|
3,095
|
0.00
|
USD 0
|
|
|
2020-01-07 |
2020-01-03 |
PS
Planned sale
|
Wentworth Kerry
Chief Regulatory Officer
|
3,724
0.00
USD 0
|
3,724
|
0.00
|
USD 0
|
|
|
2020-01-07 |
2020-01-03 |
S
Sale
|
Bodick Neil
Chief Scientific Officer
|
3,851
0.00
USD 0
|
3,851
|
0.00
|
USD 0
|
|
|
2020-01-07 |
2020-01-03 |
S
Sale
|
Willwerth Christina
Chief Strategy Officer
|
3,533
0.00
USD 0
|
3,533
|
0.00
|
USD 0
|
|
|
2019-08-09 |
2019-08-08 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
2,000
+4.6%
10.74
USD 21,480
|
2,000
+4.6%
|
10.74
|
USD 21,480
|
|
|
2019-08-08 |
2019-08-08 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
2,317
+3.3%
10.85
USD 25,136
|
2,317
+3.3%
|
10.85
|
USD 25,136
|
|
|
2019-06-03 |
2019-05-31 |
B
Purchase
|
Arkowitz David
Chief Financial Officer
|
2,500
+2.9%
11.05
USD 27,627
|
2,500
+2.9%
|
11.05
|
USD 27,627
|
|
|
2019-05-24 |
2019-05-23 |
B
Purchase
|
MERRIFIELD C ANN
Non-Executive Director
|
8,000
+400.0%
12.64
USD 101,120
|
8,000
+400.0%
|
12.64
|
USD 101,120
|
|
|
2019-05-15 |
2019-05-13 |
B
Purchase
|
Arkowitz David
Chief Financial Officer
Officer
|
4,000
+4.8%
11.99
USD 47,960
|
4,000
+4.8%
|
11.99
|
USD 47,960
|
|
|
2019-05-13 |
2019-05-10 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
4,012
+5.7%
12.48
USD 50,067
|
4,012
+5.7%
|
12.48
|
USD 50,067
|
|
|
2019-05-09 |
2019-05-08 |
PS
Planned sale
|
Arkowitz David
Chief Financial Officer
Officer
|
2,248
-2.6%
10.06
USD 22,615
|
2,248
-2.6%
|
10.06
|
USD 22,615
|
|
|
2019-03-13 |
2019-03-12 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
4,046
+6.1%
12.36
USD 50,009
|
4,046
+6.1%
|
12.36
|
USD 50,009
|
|
|
2019-01-04 |
2019-01-03 |
PS
Planned sale
|
Bodick Neil
Chief Scientific Officer
Officer
|
746
-1.1%
12.36
USD 9,221
|
746
-1.1%
|
12.36
|
USD 9,221
|
|
|
2019-01-04 |
2019-01-03 |
PS
Planned sale
|
Clayman Michael D.
President and CEO
Executive Director
|
3,278
-4.7%
12.36
USD 40,516
|
3,278
-4.7%
|
12.36
|
USD 40,516
|
|
|
2019-01-04 |
2019-01-03 |
PS
Planned sale
|
Levine Mark S.
General Counsel
Officer
|
734
-7.5%
12.36
USD 9,072
|
734
-7.5%
|
12.36
|
USD 9,072
|
|
|
2019-01-04 |
2019-01-03 |
PS
Planned sale
|
Wentworth Kerry
Chief Regulatory Officer
Officer
|
622
-5.3%
12.36
USD 7,688
|
622
-5.3%
|
12.36
|
USD 7,688
|
|
|
2019-01-04 |
2019-01-03 |
PS
Planned sale
|
KELLEY SCOTT
Chief Medical Officer
Officer
|
622
-3.9%
12.36
USD 7,688
|
622
-3.9%
|
12.36
|
USD 7,688
|
|
|
2018-11-13 |
2018-11-09 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
5,000
+7.8%
17.10
USD 85,477
|
5,000
+7.8%
|
17.10
|
USD 85,477
|
|
|
2018-11-13 |
2018-11-09 |
B
Purchase
|
Arkowitz David
Chief Financial Officer
Officer
|
4,000
+9.0%
16.56
USD 66,222
|
4,000
+9.0%
|
16.56
|
USD 66,222
|
|
|
2018-08-10 |
2018-08-09 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
10,000
+15.3%
22.33
USD 223,300
|
10,000
+15.3%
|
22.33
|
USD 223,300
|
|
|
2018-08-10 |
2018-08-09 |
B
Purchase
|
Arkowitz David
Chief Financial Officer
Officer
|
4,000
+9.9%
23.42
USD 93,680
|
4,000
+9.9%
|
23.42
|
USD 93,680
|
|
|
2018-07-03 |
2018-07-03 |
PS
Planned sale
|
Bodick Neil
Chief Scientific Officer
Officer
|
16,492
-20.9%
25.00
USD 412,300
|
16,492
-20.9%
|
25.00
|
USD 412,300
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
Bodick Neil
Chief Scientific Officer
Officer
|
33,508
-29.8%
25.10
USD 841,192
|
33,508
-29.8%
|
25.10
|
USD 841,192
|
|
|
2017-11-22 |
2017-11-21 |
B
Purchase
|
Bodick Neil
Chief Scientific Officer
|
1,000
+inf%
24.66
USD 24,656
|
1,000
+inf%
|
24.66
|
USD 24,656
|
|
|
2017-11-22 |
2017-11-21 |
B
Purchase
|
Bodick Neil
Chief Scientific Officer
|
1,700
+2.7%
24.39
USD 41,457
|
1,700
+2.7%
|
24.39
|
USD 41,457
|
|
|
2017-11-09 |
2017-11-08 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
5,000
+16.5%
23.60
USD 118,000
|
5,000
+16.5%
|
23.60
|
USD 118,000
|
|
|
2017-09-15 |
2017-09-05 |
B
Purchase
|
Deniz Yamo
Chief Medical Officer
|
1,000
+12.5%
24.20
USD 24,200
|
1,000
+12.5%
|
24.20
|
USD 24,200
|
|
|
2017-09-15 |
2017-09-01 |
B
Purchase
|
Deniz Yamo
Chief Medical Officer
|
2,000
+33.3%
23.95
USD 47,900
|
2,000
+33.3%
|
23.95
|
USD 47,900
|
|
|
2017-09-15 |
2017-09-01 |
B
Purchase
|
Deniz Yamo
Chief Medical Officer
|
1,000
+20.0%
24.55
USD 24,550
|
1,000
+20.0%
|
24.55
|
USD 24,550
|
|
|
2017-09-15 |
2017-08-31 |
B
Purchase
|
Deniz Yamo
Chief Medical Officer
|
1,375
+37.9%
25.40
USD 34,925
|
1,375
+37.9%
|
25.40
|
USD 34,925
|
|
|
2017-06-20 |
2017-06-16 |
B
Purchase
|
Stejbach Mark
|
1,580
+inf%
17.02
USD 26,888
|
1,580
+inf%
|
17.02
|
USD 26,888
|
|
|
2017-06-06 |
2017-06-05 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
5,000
+33.0%
17.23
USD 86,152
|
5,000
+33.0%
|
17.23
|
USD 86,152
|
|
|
2017-06-06 |
2017-06-05 |
B
Purchase
|
COLELLA SAMUEL D
Large shareholder
|
5,000
+inf%
17.01
USD 85,048
|
5,000
+inf%
|
17.01
|
USD 85,048
|
|
|
2017-05-17 |
2017-05-15 |
PS
Planned sale
|
Bodick Neil
Chief Medical Officer
Officer
|
1,700
-4.2%
19.39
USD 32,967
|
1,700
-4.2%
|
19.39
|
USD 32,967
|
|
|
2017-05-17 |
2017-05-15 |
PS
Planned sale
|
Bodick Neil
Chief Medical Officer
Officer
|
5,130
-11.2%
18.81
USD 96,481
|
5,130
-11.2%
|
18.81
|
USD 96,481
|
|
|
2017-04-18 |
2017-04-17 |
PS
Planned sale
|
Bodick Neil
Chief Medical Officer
|
200
-0.4%
28.86
USD 5,772
|
200
-0.4%
|
28.86
|
USD 5,772
|
|
|
2017-04-18 |
2017-04-17 |
PS
Planned sale
|
Bodick Neil
Chief Medical Officer
|
4,800
-9.4%
28.20
USD 135,360
|
4,800
-9.4%
|
28.20
|
USD 135,360
|
|
|
2017-03-24 |
2017-03-23 |
PS
Planned sale
|
DRISCOLL FREDERICK W
Chief Financial Officer
Officer
|
3,000
-27.8%
23.00
USD 69,000
|
3,000
-27.8%
|
23.00
|
USD 69,000
|
|
|
2017-03-20 |
2017-03-17 |
PS
Planned sale
|
Bodick Neil
Chief Medical Officer
|
5,000
-8.9%
20.41
USD 102,039
|
5,000
-8.9%
|
20.41
|
USD 102,039
|
|
|
2017-03-02 |
2017-02-28 |
PS
Planned sale
|
DRISCOLL FREDERICK W
Chief Financial Officer
Officer
|
600
-7.2%
20.42
USD 12,250
|
600
-7.2%
|
20.42
|
USD 12,250
|
|
|
2017-03-02 |
2017-02-28 |
PS
Planned sale
|
DRISCOLL FREDERICK W
Chief Financial Officer
Officer
|
32,834
-79.7%
19.96
USD 655,429
|
32,834
-79.7%
|
19.96
|
USD 655,429
|
|
|
2017-02-27 |
2017-02-24 |
PS
Planned sale
|
Bodick Neil
Chief Medical Officer
|
5,000
-8.2%
19.15
USD 95,758
|
5,000
-8.2%
|
19.15
|
USD 95,758
|
|
|
2017-01-23 |
2017-01-20 |
PS
Planned sale
|
Bodick Neil
Chief Medical Officer
|
5,000
-7.6%
18.35
USD 91,747
|
5,000
-7.6%
|
18.35
|
USD 91,747
|
|
|
2016-12-22 |
2016-12-21 |
PS
Planned sale
|
Bodick Neil
Chief Medical Officer
Officer
|
10,000
-13.2%
18.46
USD 184,628
|
10,000
-13.2%
|
18.46
|
USD 184,628
|
|
|
2016-12-05 |
2016-12-01 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
10,000
+30.0%
16.38
USD 163,807
|
10,000
+30.0%
|
16.38
|
USD 163,807
|
|
|
2016-11-23 |
2016-11-23 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
1,667
+5.7%
18.41
USD 30,688
|
1,667
+5.7%
|
18.41
|
USD 30,688
|
|
|
2016-11-23 |
2016-11-22 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
1,666
+6.1%
17.95
USD 29,900
|
1,666
+6.1%
|
17.95
|
USD 29,900
|
|
|
2016-11-22 |
2016-11-21 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
33,333
+inf%
18.00
USD 599,994
|
33,333
+inf%
|
18.00
|
USD 599,994
|
|
|
2016-11-22 |
2016-11-21 |
B
Purchase
|
Clayman Michael D.
President and CEO
Executive Director
|
1,666
+6.5%
17.90
USD 29,827
|
1,666
+6.5%
|
17.90
|
USD 29,827
|
|
|
2016-06-22 |
2016-06-21 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
400
+1.6%
13.71
USD 5,483
|
400
+1.6%
|
13.71
|
USD 5,483
|
|
|
2016-06-22 |
2016-06-21 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
504
+2.0%
13.65
USD 6,881
|
504
+2.0%
|
13.65
|
USD 6,881
|
|
|
2016-06-22 |
2016-06-21 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
4,600
+23.0%
13.76
USD 63,288
|
4,600
+23.0%
|
13.76
|
USD 63,288
|
|
|
2016-06-22 |
2016-06-21 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
13,222
+195.1%
13.62
USD 180,114
|
13,222
+195.1%
|
13.62
|
USD 180,114
|
|
|
2016-06-22 |
2016-06-20 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
3,343
+97.3%
13.70
USD 45,813
|
3,343
+97.3%
|
13.70
|
USD 45,813
|
|
|
2016-06-22 |
2016-06-20 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
3,435
+inf%
13.98
USD 48,020
|
3,435
+inf%
|
13.98
|
USD 48,020
|
|
|
2016-06-16 |
2016-06-14 |
B
Purchase
|
MERRIFIELD C ANN
Non-Executive Director
|
1,000
+100.0%
13.39
USD 13,387
|
1,000
+100.0%
|
13.39
|
USD 13,387
|
|
|
2016-06-10 |
2016-06-08 |
B
Purchase
|
LUBASH BARBARA N
Large shareholder
|
4,194
+25.3%
14.00
USD 58,716
|
4,194
+25.3%
|
14.00
|
USD 58,716
|
|
|
2016-06-10 |
2016-06-08 |
B
Purchase
|
COLELLA SAMUEL D
Non-Executive Director
Large shareholder
|
4,194
+25.3%
14.00
USD 58,716
|
4,194
+25.3%
|
14.00
|
USD 58,716
|
|
|
2016-06-10 |
2016-06-08 |
B
Purchase
|
Versant Ventures III, LLC
Large shareholder
|
4,194
+25.3%
14.00
USD 58,716
|
4,194
+25.3%
|
14.00
|
USD 58,716
|
|
|
2016-06-10 |
2016-06-08 |
B
Purchase
|
LUBASH BARBARA N
Large shareholder
|
710,091
+25.3%
14.00
USD 9,941,274
|
710,091
+25.3%
|
14.00
|
USD 9,941,274
|
|
